--- title: "After two consecutive setbacks, Yatai Pharm accelerates its strategic transformation in the innovative drug industry" type: "News" locale: "en" url: "https://longbridge.com/en/news/288080248.md" description: "Yatai Pharm's wholly-owned subsidiary, Yatai Lizhong, plans to jointly establish two specialized funds, Qizhen Zhijian and Qizhen Zhikang, with investment institutions, to invest in Xiwai Biotechnology and Yisheng Biotechnology, respectively. This move aims to leverage capital to layout in the fields of innovative drugs, regenerative medicine, and chronic disease treatment, deepen industrial synergy, optimize business structure, and enhance core competitiveness" datetime: "2026-05-29T13:57:10.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/288080248.md) - [en](https://longbridge.com/en/news/288080248.md) - [zh-HK](https://longbridge.com/zh-HK/news/288080248.md) --- # After two consecutive setbacks, Yatai Pharm accelerates its strategic transformation in the innovative drug industry On the evening of May 29, 2026, Zhejiang Yatai Pharmaceutical Co., Ltd. (hereinafter referred to as: Yatai Pharmaceutical, stock code: 002370.SZ) announced that its wholly-owned subsidiary Yatai Lizhong plans to jointly establish two specialized industrial funds with professional investment institutions, aimed at investing in Ximei (Suzhou) Biomedical Technology Co., Ltd. and Hangzhou Yisheng Biotechnology Co., Ltd. in a way that promotes capital linkage and industrial synergy, continuously increasing its investment in innovative drugs and cutting-edge medical technology. The two specialized funds, Qizhen Zhijian and Qizhen Zhikang, will be funded by Yatai Lizhong as a limited partner using its own funds, relying on the industry resources, investment research capabilities, and fund management experience of professional investment institutions. While ensuring the company's daily operational funding needs, the funds will precisely target high-growth pharmaceutical research and development projects, focusing on the main business by investing in innovative drugs, high-end medical devices, regenerative medicine, chronic inflammation, and major chronic disease treatment fields. In the future, the company is expected to further deepen cooperation with the targeted investments and expand its business layout. Ximei Biomedical focuses on the research and industrialization of non-source implantable medical devices, with a core focus on regenerative medical devices such as bionic corneas. Its research pipeline includes artificial corneas, implantable contact lenses (EVL), artificial dermis, and corneal endothelial sheets. It is understood that Ximei Biomedical aims to "build a biomaterials platform connecting silicon-based and carbon-based life," focusing on breakthroughs in synthetic collagen biomimetic technology—its core material is chemically synthesized peptides, which have no animal-derived virus risk, controllable purity, and can self-assemble through a triple helix structure. It can polymerize with bioactive substances and polymer materials, possessing characteristics such as regenerative repair and drug sustained release, while addressing the safety and functionality pain points of traditional biomaterials, and has broad potential for expansion into ophthalmology, sports medicine, and medical aesthetics. Yisheng Biotechnology focuses on the research and development of Class 1.1 new drugs for chronic inflammation and major chronic diseases, using inflammatory mechanisms as a breakthrough to explore new drug targets and treatment plans, providing innovative solutions for chronic disease prevention and treatment, forming a high degree of synergy with Yatai Pharmaceutical's existing formulation business, and helping the company reserve high-quality innovative drug projects. Yatai Pharmaceutical stated that by participating in professional industrial funds, the company can efficiently reserve high-quality R&D projects and expand into cutting-edge pharmaceutical tracks. In the future, it will further deepen industrial cooperation with the targeted enterprises, optimize its business structure, enhance core competitiveness and sustainable development capabilities, and create long-term value for shareholders. As a well-established pharmaceutical company deeply engaged in the chemical formulation field in China, Yatai Pharmaceutical is firmly advancing a strategy that combines imitation and innovation, accelerating its transformation into an innovative pharmaceutical enterprise. Since the new controlling shareholder Qiu Zhongxun and the major shareholder Xinghao Holdings took over, the company has received comprehensive resource empowerment, continuously implementing support in funding, channel expansion, and innovative drug production line construction, significantly accelerating the pace of innovation transformation. Previously, Yatai Pharmaceutical had reached a strategic cooperation agreement with the pharmaceutical industry internet platform Yaodou Technology, which is under the control of its actual controller, to promote the digitalization of pharmaceutical retail, smart health services, and supply chain collaborative optimization, building a one-stop health management ecosystem of "medicine + healthcare, online + offline, products + services." The company has established a wholly-owned platform, Yatai Lizhong, which has quickly completed cooperation layouts in the pharmaceutical circulation field, focusing on the introduction, development, and market promotion of high-quality products, broadening profit channels and cultivating new growth drivers This strategic investment in two innovative pharmaceutical companies is a key move in Yatai Pharm's innovative drug strategy. Relying on the industrial resources and market-oriented capital operations of its controlling shareholder, the company is forming a diversified and collaborative pattern of "generic drug base + innovative drug growth pole," with a clear path for high-quality development and continuous improvement in certainty ### Related Stocks - [002370.CN](https://longbridge.com/en/quote/002370.CN.md) ## Related News & Research - [Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio | RVVTF Stock News](https://longbridge.com/en/news/296357987.md) - [Regenerative Medical Technology Group announces investor call to address shareholder questions](https://longbridge.com/en/news/296410031.md) - [Vector Science files US provisional patent for orthopedic tissue-regeneration peptide platform](https://longbridge.com/en/news/296483037.md) - [Faeth Therapeutics wins FDA fast-track status for PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer](https://longbridge.com/en/news/296098241.md) - [BioNxt completes IMPD, moves toward first human bioequivalence trial for sublingual cladribine film in MS](https://longbridge.com/en/news/296314929.md)